Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
A 12.4-Million-Cell Map Links Two T-Cell States to Different Ageing Trajectories
A global single-cell study linked the balance of granzyme K- and granzyme B-producing T cells to later disease and mortality. It is an association, not a clinical test.
-
Lung Organoids Reveal How Chronic Smoke Primes Distinct Cancer Pathways
Six months of smoke exposure pushed mouse lung organoids into precancerous states that responded differently to KRAS and TP53 changes. The work is preclinical.
-
AI-Guided Formulation Keeps Experimental mRNA Vaccines Stable at 37°C
An AI-guided formulation kept dried mRNA–lipid nanoparticles active after months at warm temperatures in animal studies. Human testing and manufacturing validation remain ahead.
-
Optogenetic Therapy Restores Light Detection in a 10-Person Blindness Trial
A gene therapy plus light-projecting goggles increased light sensitivity in seven people with advanced retinitis pigmentosa. The early trial did not restore normal sight.
-
MolGenBench Finds AI Molecule Generators Struggle on Real Drug-Discovery Tasks
A peer-reviewed benchmark of 17 generative models found weak target awareness, risky chemical motifs and poor generalisation. Better-looking molecules are not yet better drugs.
-
Prime Editing Enters the Liver as PM577a Doses Its First Wilson Disease Patient
Prime Medicine has begun a first-in-human Phase I/II study of an in-vivo prime editor for Wilson disease. The milestone starts the safety test; it supplies no efficacy result yet.
-
Gum-Derived Stem Cells Show a Signal in an 18-Person Type 1 Diabetes Trial
A small randomised Phase I trial linked gingiva-derived cells to stronger C-peptide signals and lower insulin requirements. The result is preliminary and not a cure.
-
RYZ101’s Phase III Win Brings Actinium-225 Cancer Therapy to a Regulatory Test
A planned interim analysis found longer progression-free survival with RYZ101. The topline result advances targeted alpha therapy without yet supplying the full evidence.
-
AI Drug Development Is Taking on the Chemistry of Long-Acting Injections
A company-authored preprint uses AI to balance release, loading and injectability in polymer depots. Its 30-day release profiles are laboratory results.
-
Long-Telomere Families Expose a Trade-Off in Longevity Biology
A study of rare POT1 variants links unusually long telomeres to persistent cell lineages and cancer susceptibility, challenging a simple longevity target.
-
CAR Macrophages Reach Solid Tumours, but Stable Disease Is Only a Starting Point
Engineered macrophages reached tumours in a small Phase I study. The results separate cell delivery and manufacturing from evidence of cancer control.
-
AI-Designed Phage Genomes Cross a Laboratory Threshold
Researchers generated complete bacterial-virus genomes and found viable candidates in laboratory tests. This validates a design capability, not a patient treatment.